Article
Cetuximab Resistance in Head and Neck Cancer Is Mediated by EGFR-K521 Polymorphism.
Cancer research - 1 Mar 2017
Braig Friederike, Kriegs Malte, Voigtlaender Minna, Habel Beate, Grob Tobias, Biskup Karina, Blanchard Veronique, Sack Markus, Thalhammer Anja, Ben Batalla Isabel, Braren Ingke, Laban Simon, Danielczyk Antje, Goletz Steffen, Jakubowicz Elzbieta, Märkl Bruno, Trepel Martin, Knecht Rainald, Riecken Kristoffer, Fehse Boris, Loges Sonja, Bokemeyer Carsten, Binder Mascha
Abstract excerpt
Head and neck squamous cell carcinomas (HNSCC) exhibiting resistance to the EGFR-targeting drug cetuximab poses a challenge to their effective clinical management. Here, we report a specific mechanism of resistance in this setting based upon the presence of a single nucleotide polymorphism encoding EGFR-K521 (K-allele), which is expressed in >40% of HNSCC cases. Patients expressing the K-allele showed...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.